Scinai Immunotherapeutics Ltd. American Depositary Shares (SCNI)

Scinai Announces New Peer-Reviewed Publication Supporting PC111 as a Disease-Modifying Therapy for Pemphigus and SJS/TEN

Scinai Immunotherapeutics published research validating PC111, a novel monoclonal antibody targeting pemphigus and Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), demonstrating potential as a disease-modifying therapy with a unique non-immunosuppressive mechanism.

Scinai Immunotherapeutics Provides Update Regarding Nasdaq Compliance

JERUSALEM, Nov. 03, 2023 (GLOBE NEWSWIRE) -- via IBN – Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases, today announced receipt of a letter from the Nasdaq Stock Market ("Nasdaq") dated November 1, 2023, regarding non-compliance with the requirement to maintain a minimum bid price of $1.00 per share.